Microbix Biosystems Inc represents the values of exceptional innovation, dedication to quality, and commitment to customer satisfaction. As a leading biotechnology company, Microbix is driven by a strong corporate philosophy centered on advancing human health through the development and production of high-quality diagnostic reagents and viral antigens. With a focus on continuous improvement, Microbix strives to deliver superior products and services to meet the evolving needs of the healthcare industry. By prioritizing research and development, along with stringent quality control measures, Microbix Biosystems Inc ensures its reputation as a trusted provider of essential biological products.

Microbix Biosystems Inc is primarily present in Canada, United States, Europe, and Asia.

Microbix Biosystems Inc, a leading life science company, has accomplished several significant milestones. Notably, the company successfully developed and launched key products in the virology industry, including Quality Assessment (QA) controls for viral diseases and viral antigens. Microbix Biosystems Inc also introduced innovative technologies like the Kinlytic Urokinase, a clot-dissolving agent. Through strategic partnerships, the company expanded its global presence and garnered recognition for its exceptional research and development capabilities. Furthermore, Microbix Biosystems Inc achieved ISO 13485 certification, validating its commitment to quality management systems. These achievements solidify the company's position as a prominent player in the biotechnology sector.

Microbix Biosystems Inc is a well-established company with a rich history and background. Founded in 1988, Microbix has grown to become a leading provider of biological products and technologies worldwide. The company specializes in the development, manufacture, and distribution of biological materials used in the diagnostics, research, and quality control fields. With its state-of-the-art facilities and dedicated team of experts, Microbix has consistently delivered innovative solutions to the global life sciences industry. Their wide range of products and services includes viral antigens, quality assessment programs, and proficiency panels. Throughout its history, Microbix Biosystems Inc has remained committed to providing high-quality products and contributing to advancements in the healthcare sector.

The main competitors of Microbix Biosystems Inc in the market include companies such as Becton, Dickinson and Company (BD), Bio-Rad Laboratories, and Meridian Bioscience Inc.

Microbix Biosystems Inc is primarily active in the fields of virology and molecular diagnostics.

Microbix Biosystems Inc is a leading biotechnology company with a robust business model focused on developing and commercializing innovative biological products. The company specializes in producing and marketing unique biological substances, such as antigens and quality assessment controls, for diagnostic testing and scientific research. Microbix Biosystems Inc leverages its extensive expertise in virology, immunology, and bioprocessing to provide high-quality products to diagnostic laboratories, biopharmaceutical companies, and research institutions worldwide. With a continued commitment to advancing healthcare and scientific research, Microbix Biosystems Inc has established a strong reputation as a trusted partner in the industry.

Коефициентът на цена спрямо печалбата (КЦП) на Microbix Biosystems е 18,77.

Коефициентът на цена към оборот (KUV) на Microbix Biosystems е 2,03.

AlleAktien качественият резултат за Microbix Biosystems е 5/10.

очаквана Microbix Biosystems оборотът е 25,45 млн. CAD.

очаквана Microbix Biosystems печалба е 2,76 млн. CAD.

Microbix Biosystems Inc is a Toronto-based biotechnology company that focuses on researching, developing, and marketing diagnostic and therapeutic products. The company operates in three business areas: Diagnostic test systems, infectious diseases, and bioproducts.

Microbix Biosystems разпределя дивидента от 0 CAD на плащания годишно.

Дивидентата за Microbix Biosystems в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Microbix Biosystems е CA59501P1045.

WKN на Microbix Biosystems е 935162.

Тикерът на Microbix Biosystems е MBX.TO.

През последните 12 месеца Microbix Biosystems изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Microbix Biosystems да изплати дивиденда в размер на 0 CAD.

Дивидентната доходност на Microbix Biosystems в момента е .

Microbix Biosystems изплаща дивидент на тримесечие. Той се разпределя в месеците .

Microbix Biosystems платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 CAD. Това съответства на дивидентна доходност от 0 %.

Microbix Biosystems се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Microbix Biosystems на 7.09.2024 г. в размер на 0 CAD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 7.09.2024 г..

Последното дивидентно плащане беше извършено на 7.09.2024 г..

През година 2023 Microbix Biosystems изплати 0 CAD под формата на дивиденти.

Дивидентите от Microbix Biosystems се изплащат в CAD.